Neoagarooligosaccharides (Dyne-NAO)
Introduction
Dyne Bio Inc. has developed a new bioactive compound from red algae, Gelidium elegans.
Dyne-NAO is obtained by decomposing agar which is a major component of red algae, Gelidium elegans.
that is one of Korea’s main marine resources. We produce neoagarotetraose(DP4) and neoagarohexaose(DP6)
through the enzymatic bio conversion process. As a new bioactive compound, we verified their effectiveness and safety.
Currently we are working on developing them as food and pharmaceutical materials.
Dyne-NAO was completed safety evaluations and has significant effects on improving metabolic syndrome
(obesity, diabetes and hyperlipidemia), immune modulation, moisturizing and anti-oxidant. Consequently,
we are promoting business with Dyne-NAO as a high value functional biomaterial.
Structure of Dyne-NAO
Category | Compound | DP4 | DP6 |
---|---|---|
CAS registry number | 16033-31-1 | 25023-93-2 |
Molecular weight | 630.547 | C24H38O19 |
Molecular formula | C24H38O19 | C36H56O28 |
Biological efficacy
Efficacy | Biological activity |
---|---|
Metabolic Syndrome- Obesity- Diabetes- Hyperlipidemia- Hepatic injury |
• Obesity- Reduction of the adipocytes size - Upregulation of lipolysis related gene expression - Downregulation of lipogenesis related gene expression • Diabetes- Improvement of insulin resistance - Improvement of glycemic control • Hyperlipidemia- Improvement of serum lipid profiling - Upregulation of lipid receptor related gene expression (SREBP2, PCSK9) • Hepatic injury- Activation of antioxidant genes via Nrf2 activation for acute liver damage - Prevention and treatment of chronic liver injury via inhibition of |
Immune system |
• Immune cell stimulation- Macrophage, NK cells, T cells, etc. • Dendritic cells maturation- Activation of NK, Non NK immunocyte - Identification of Toll-like Receptor (TLR) • Inhibition of tumor growth (in vivo)• Prevention & treatment of Microbial infection (in vivo)• Preventing & improving sepsis (in vitro, in vivo)• Improving & treating rheumatoid arthritis and atopic dermatitis• Anti-viral effect against Norovirus |
Patent
No | Patent | Registration No. (Registration Date : DD/MM/YYYY) |
---|---|---|
1 |
Agar-derived neoagarooligosaccharide complex for the prevention and treatment of obesity and/or diabetes comprising enzyme reaction products of beta agarase DagA and agar |
Rep. of Korea 10-1632262 (15/06/2016) |
Japan JP6088657 (10/02/2017) |
||
China ZL201380059074.6 (23/06/2017) |
||
2 |
Composition comprising neoagarooligosaccharide for preventing or treating sepsis or septic shock |
Rep. of Korea 10-1675359 (07/11/2016) |
U.S. 10,548,916 (04/02/2020) |
||
China ZL 201580075360.0 (26/06/2020) |
||
3 |
Composition for preventing, alleviating, or treating arthritis or osteoporosis, containing neoagarooligosaccharide |
Rep. of Korea 10-1923062 (22/11/2018) |
Japan JP6815525 (24/12/2020) |
||
U.S. 10,933,086 (02/03/2021) |
||
4 |
Mutant strain of Streptomyces coelicolor, method for producing β-agarase using the same and method for manufacturing neoagarooligosaccharide using the same |
Rep. of Korea 10-1919962 (13/11/2018) |
5 | Manufacturing method of agar for raw material of neoagarooligosaccharide mixture and use thereof |
Rep. of Korea 10-2214973 (04/02/2021) |
Articles
- Anti-Obesity and Anti-Diabetic Effect of Neoagarooligosaccharides on High-Fat Diet-Induced Obesity in Mice. Marine drugs. 2017;15(4):90.
- Neoagarooligosaccharides enhance the level and efficiency of LDL receptor and improve cholesterol homeostasis. Journal of Functional Foods. 2017;38:529-539.
- Neoagarohexaose-mediated activation of dendritic cells via Toll-like receptor 4 leads to stimulation of natural killer cells and enhancement of antitumor immunity. BMB Reports. 2017;50(5):263-268.
- Neoagarooligosaccharides prevent septic shock by modulating A20- and cyclooxygenase-2–mediated interleukin-10 secretion in a septic-shock mouse model. BBRC. 486(4), 998-1004, 2017.
- Toxicological evaluation of neoagarooligosaccharides prepared by enzymatic hydrolysis of agar. Regulatory Toxicology and Pharmacology. 2017;90:9-21.
- In vitro and in vivo Investigation for Biological Activities of Neoagarooligosaccharides Prepared by Hydrolyzing Agar with β-Agarase. Biotechnology and Bioprocess Engineering. 2017;22:489-496.
- Safety evaluation of β-agarase preparations from Streptomyces coelicolor A3(2). Regulatory Toxicology and Pharmacology. 2019; 101, 142-155.
- Non-targeted metabolomics unravels a media-dependent prodiginines production pathway in Streptomyces coelicolor A3(2). PLoS ONE. 2018;13(11): e0207541.
- Implications of agar and agarase in industrial applications of sustainable marine biomass. Applied Microbiology and Biotechnology 2020;104:2815–2832.
- Hepatoprotective effect of neoagarooligosaccharide via activation of Nrf2 and enhanced antioxidant efficacy. Biol Pharm Bull. 2020;43(4), 619-628.
- Antiviral efficacy of orally delivered neoagarohexaose, a nonconventional TLR4 agonist, against norovirus infection in mice. Biomaterials 2020;263, 120391.
- Neoagarooligosaccharide Protects Against Hepatic Fibrosis via inhibition of TGF‐β/Smad Signaling Pathway. Int. J. Mol. Sci. 2021;22. 2041.